Epidermal growth factor receptor (EGFR) amplification and mutations are frequently observed in IDH‐wildtype glioblastomas, which are associated with poor prognosis and represent potential targets for molecular therapies [3, 4]. Here, IDH2 is linked to glioblastoma.